Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis


The primary objective is to evaluate the safety of an investigational compound, BLXA4-ME, topically applied as a daily oral rinse in adults with gingivitis. Safety will be assessed by the incidence of adverse events, including mucosal inflammation and irritancy and findings from safety labs. Subjects will be monitored for development of periodontitis, and oral flora will be analyzed to detect an increase in opportunistic organisms. The secondary objective is to assess preliminary efficacy of the oral rinse, by monitoring changes in the plaque index (PI), modified gingival index (MGI), bleeding on probing (BOP) and levels of interleukin -1? (IL-1?) in gingival crevicular fluid (GCF). The study comprises three groups in a randomized, placebo-controlled double-blind clinical trial design. The treatment group (1.0 ?M BLXA4-ME oral rinse) and the placebo rinse group will each include 50 subjects. The no-rinse control group will consist of 25 subjects. Subjects in the treatment and placebo rinse groups will receive oral rinse (BLXA4-ME or placebo) to be applied once daily after morning teeth brushing. Safety parameters will be assessed before and after 3, 7, 14, 21, and 28 days of treatment. Efficacy parameters will be assessed before and after 14 and 28 days of treatment.

Study Start Date

April 2015

Estimated Completion Date

December 2016


  • Drug: BLXA4
  • Drug: Placebo oral rinse


  • Dentistry: Periodontics

MeSH Terms

  • BLXA4
  • Gingivitis
  • Inflammation

Study ID

The Forsyth Institute -- 14-020-E



Trial ID


Study Type


Trial Phase

Phase 1/Phase 2

Enrollment Quota



The Forsyth Institute

Inclusion Criteria

  • Signed consent form
  • Good general health as evidenced by medical history
  • Age 18
  • 65
  • Must have a stable address and be available for the duration of the study
  • Must have a minimum of 20 natural teeth, excluding third molars
  • Must have a mean full mouth MGI of at least 2.0
  • Must be willing to use prescribed oral hygiene procedures and products
  • Medications for chronic conditions must be stable for at least 3 months prior to enrollment
  • Women of reproductive potential must use licensed hormonal contraception or double barrier methods
  • Men of reproductive potential must agree to use condoms
  • Hemoglobin, hematocrit, white blood cells (WBC), platelets, erythrocyte sedimentation rate, creatinine, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, electrolytes (sodium, potassium, chloride, carbon dioxide) must be within ±10% of the normal laboratory range
  • Urinalysis results, including pH, protein, glucose, ketone bodies, hemoglobin, WBCs, and nitrites must be within ±10% of the normal laboratory range

Exclusion Criteria

  • Presence of orthodontic appliances or removable partial dentures
  • Presence of a soft tissue tumor of the oral cavity
  • Presence of gross plaque or calculus (? 75% of tooth surfaces)
  • Presence of extensive restorations that could affect the marginal gingiva (at the investigators' discretion)
  • Preexisting oral pathology, including carious lesions requiring immediate treatment or ulcerations of the mucosa
  • Current participation in another clinical trial or product test
  • Pregnant or breast feeding
  • Residence in the same household as a subject currently enrolled in the study (due to potential blinding and compliance issues)
  • Concomitant endodontic therapy or periodontal therapy other than prophylaxis within the past 6 months
  • Periodontitis as indicated by 3 or more sites with PD of 5 millimeters or more and CAL of 3 millimeters or more
  • History of early onset periodontitis or acute necrotizing ulcerative gingivitis
  • Chronic disease with concomitant oral manifestations, such as autoimmune or immunosuppressive diseases (e.g., human immunodeficiency virus, severe combined immunodeficiency, neutropenia, juvenile arthritis, systemic lupus erythematosus, sickle cell anemia, Crohn's disease, rheumatoid arthritis, Sjögren's syndrome) or immunocompromised status due to cancer chemotherapy, hematopoietic stem cell or solid organ transplant, head and neck radiotherapy, splenectomy, chronic steroid usage
  • Recent history of chronic alcohol consumption of more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer, or five 5 ounce servings of wine per day
  • Tobacco use (former tobacco users may be enrolled, provided they have been tobacco-free for one year or more)
  • Diabetes mellitus
  • Medical conditions that the investigator considers significant and that may interfere with the examination or the safety of the subject
  • Chronic use (2 weeks or more) of medication known to affect periodontal status within one month of enrollment (such as ?81mg aspirin, phenytoin, calcium antagonists such as nifedipine, NSAIDs, coumarin, cyclosporine, ?10 mg/day atorvastatin or equivalent dose of another statin [Subramanian et al, 2013])
  • Treatment with antibiotics within one month prior to enrollment
  • Medical condition for which antibiotic treatment during the study period is likely or a condition for which antibiotic prophylaxis is recommended before dental procedures (American Heart Association guidelines of 2007 will be followed)
  • Known hypersensitivity to any component of the test or placebo products
  • Anything that, in the opinion of the investigator, would place the subject at increased risk or prevent the subject from fully complying with or completing the study -




18 Years to 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
The Forsyth Institute - Cambridge, Massachusetts 2.3 miles Hatice Hasturk DDS PhD 617-892-8499 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.